Article

IOL range expands

An IOL (Softec HD, Lenstec) for treating cataracts now is available in an expanded range of prescriptions, covering 15.0 to 25.0 D. Since its approval by the FDA in April 2010, it had been available in mid-range powers between 18.0 and 25.0 D.

St. Petersburg, FL-An IOL (Softec HD, Lenstec) for treating cataracts now is available in an expanded range of prescriptions, covering 15 to 25 D. Since its approval by the FDA in April 2010, it had been available in mid-range powers between 18 and 25 D.

The bi-aspheric IOL has a stable uniplanar design and is manufactured to a tolerance of ±0.11 D, making it the most predictable IOL on the U.S. market, according to the company, which notes that the industry standard 0.40-D tolerance is set in accordance with less-stringent ISO guidelines.

The company’s proprietary manufacturing process is designed to reduce variability and produce the IOL in non-overlapping 0.25-D increments throughout its full 15- to 25-D range. In contrast, most IOLs are manufactured in 0.50-D increments that may overlap, according to the company.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.